StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) stock

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.99+0.19 (+1.13%)

Close on Nov 18, 2026Market cap $3.10BP/E –Yield –

Xeris Biopharma operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Xeris Biopharma's operating cash flow for the twelve months ending Jun 30, 2026 was $56.61M. For fiscal 2025 it was $28.63M. The highest annual figure on record is $28.63M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$28.63M–
FY2024Dec 31, 2024-$36.98M–
FY2023Dec 31, 2023-$47.02M–
FY2022Dec 31, 2022-$102.89M–
FY2021Dec 31, 2021-$95.54M–
FY2020Dec 31, 2020-$80.56M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$8.26M+4440.1%
Q1 FY2026Mar 31, 2026$9.87M–
Q4 FY2025Dec 31, 2025$20.04M+914.8%
Q3 FY2025Sep 30, 2025$18.43M–
Q2 FY2025Jun 30, 2025$182.00K–
Q1 FY2025Mar 31, 2025-$10.03M–
Q4 FY2024Dec 31, 2024$1.98M-73.6%
Q3 FY2024Sep 30, 2024-$8.31M–
Q2 FY2024Jun 30, 2024-$10.35M–
Q1 FY2024Mar 31, 2024-$20.30M–
Q4 FY2023Dec 31, 2023$7.47M–
Q3 FY2023Sep 30, 2023-$14.61M–
Q2 FY2023Jun 30, 2023-$13.74M–
Q1 FY2023Mar 31, 2023-$26.14M–
Q4 FY2022Dec 31, 2022-$16.12M–
Q3 FY2022Sep 30, 2022-$17.75M–
Q2 FY2022Jun 30, 2022-$20.61M–
Q1 FY2022Mar 31, 2022-$48.41M–
Q4 FY2021Dec 31, 2021-$28.95M–
Q3 FY2021Sep 30, 2021-$22.61M–
Q2 FY2021Jun 30, 2021-$20.02M–
Q1 FY2021Mar 31, 2021-$23.96M–
Q4 FY2020Dec 31, 2020-$10.87M–

More Xeris Biopharma figures

See a number that looks wrong?